IDMC recommends discontinuation of ADAPT phase 3 clinical trial of rocapuldencel-T
Argos Therapeutics announced the IDMC for the company's pivotal Phase 3 ADAPT clinical trial of rocapuldencel-T in combination with sunitinib/standard-of-care for treatment of mRCC has recommended the study be discontinued for futility based on its planned interim data analysis. February 22, 2017